All News
ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Read Article
Sedentary Behavior Increases the Risk of Gout
NHANES national survey study shows that sedentary behavior is an independent risk factor for gout, especially in those without hyperuricemia.
A Modifiable Vascular Risk in SLE
d
MedPage Today
Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.
Read Article
Best of 2024: BSR Guidelines for Systemic Sclerosis Management
The British Society for Rheumatology has updated its 2015 guidelines for the management of patients with systemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.
Read Article
JAK inhibitors are effective at repigmentation in vitiligo. 5 RCTs, 1,550 pts showed >50% improvement (TVASI50; RR 2.67) or >75% (FVASI75; RR 3.97_ JAKi increased skin AE, but not significantly different from placebo pts. https://t.co/zIreYlUyLt https://t.co/pCWKL2vSVs
Dr. John Cush RheumNow ( View Tweet)
Antiviral prophylaxis is essential for HBsAg+ patients receiving cytokine inhibitors, given the high risk of reactivation. Metanalysis of 10 studies shows reactivation in 21% of HBsAg+ patients without prophylaxis vs 4.4% in HBsAg−/HBcAb+ patients. https://t.co/eHzIeA8uJK https://t.co/CmZw8C8ibn
Dr. John Cush RheumNow ( View Tweet)
Outcomes Comparison study of late-onset RA (LORA) vs younger-onset RA (YORA) showed similar Dz activity assessments over 5 years but Late onset RA had worse functional outcomes and more adverse events (adj HR 4.7 for death & 2.6 for malignancy). https://t.co/b58zJG1OuA https://t.co/WZa12O06Rf
Dr. John Cush RheumNow ( View Tweet)
Online survey of 1,531 in 2019 showed that rural women have greater psychological and physical burdens than their suburban/urban women - with more mood swings, muscle and joint pain, vaginal dryness and urinary problems . https://t.co/TlaEEENdzp https://t.co/TTtyWK5urZ
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event.
https://t.co/vkoA3UHZGg
Don’t miss expert insights on JAK Inhibitors from:
🔹 Madelaine Feldman, MD
🔹 Joseph F. Merola, MD
🔹 Christina Charles-Schoeman, MD… https://t.co/jIzOzPIcML https://t.co/EB2clBvq0g
Links:
Dr. John Cush RheumNow ( View Tweet)
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/dFRnmGMGls https://t.co/LNoCtmtVuI
Links:
Dr. John Cush RheumNow ( View Tweet)
Algorithm for the treatment of calcinosis #calcinosis @RheumNow #ACR24 https://t.co/NZhP7Enzrp https://t.co/1mO8waM5DI
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Eating for Rheumatoid Arthritis
https://t.co/gtK3F6FdEB https://t.co/ILA6lSohh7
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/rFOW4OpZS7 https://t.co/A0EN8b9KYB
Dr. John Cush RheumNow ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis
Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction?
#ACR24 @RheumNow Abstr#0670 https://t.co/dr3M3cnjRG https://t.co/1wewEuJRAl
Links:
Dr. John Cush RheumNow ( View Tweet)
Overview of Uveitis management of adult & pediatric rheumatology.
- Uveitis accounts for 10% of visual impairment globally
- TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/fwhTxEpVG0 https://t.co/cKGdcDbz3d
Dr. John Cush RheumNow ( View Tweet)
A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/PMVn5Pb1b3
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus
https://t.co/zLxEOnWjpB https://t.co/I8jBcxO6rH
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency
https://t.co/atoMR1YChT https://t.co/OeaF9QUGEz
Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD.
30% of ILD has cough
Chest CT 91% sensitive, 71% specific
5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality
Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/FKZyNU1s06 https://t.co/w5q0hOesEH
Dr. John Cush RheumNow ( View Tweet)
What is Osteoarthritis? A downloadable patient education page from JAMA. https://t.co/PfoimFgxRp https://t.co/WVQbofTzGC
Dr. John Cush RheumNow ( View Tweet)